Mahmut Bayik

Mahmut Bayik

Auto-generated profile, based on publicly available information

Mahmut Bayik

Department of Internal Medicine and Hematology Marmara University Istanbul Turkey

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 October 2024 in Allergy
Verified
Journal Article
Open access
Na SunNa Sun
Na Sun
IOIsmail Ogulur
Ismail Ogulur
YMYasutaka Mitamura
Yasutaka Mitamura
DYDuygu Yazici
Duygu Yazici
YPYagiz Pat
Yagiz Pat
CACezmi A. Akdis
Cezmi A. Akdis
The prevalence of many chronic noncommunicable diseases has been steadily rising over the past six decades. During this time, over 350,000 new chemical substances have been introduced to the lives of humans. In recent years, the epithelial barrier theory came to light explaining the growing prevalence and exacerbations of these diseases worldwide. It attributes their onset to a functionally impaired epithelial barrier triggered by the toxicity of the exposed substances, associated with microbial dysbiosis, immune system activation, and inflammation. Diseases encompassed by the epithelial barrier theory share common features such as an increased prevalence after the 1960s or 2000s that cannot (solely) be accounted for by the emergence of improved diagnostic methods. Other common traits include epithelial barrier defects, microbial dysbiosis with loss of commensals and colonization of opportunistic pathogens, and circulating inflammatory cells and cytokines. In addition, practically unrelated diseases that fulfill these criteria have started to emerge as multimorbidities during the last decades. Here, we provide a comprehensive overview of diseases encompassed by the epithelial barrier theory and discuss evidence and similarities for their epidemiology, genetic susceptibility, epithelial barrier dysfunction, microbial dysbiosis, and tissue inflammation.

1 July 2000 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
TBTulin Budak-Alpdogan
Tulin Budak-Alpdogan
YTYucel Tangün
Yucel Tangün
SKSevgi Kalayoglu-Besisik
Sevgi Kalayoglu-Besisik
SRSiret Ratip
Siret Ratip
HAHamdi Akan
Hamdi Akan
HKHaluk Koç
Haluk Koç
In general, tuberculosis (Tb) is rarely seen in allogeneic stem cell transplant (alloSCT) recipients, but this observation has been challenged in developing countries such as Turkey, where Tb infection is more prevalent than in Europe and the US. In this retrospective study, we report on the incidence of Tb infections in 351 alloSCT recipients at 4 bone marrow transplantation units in Turkey over the last 10 years. The frequency of Tb in alloSCT recipients after allografting (5 of 351) was far greater than that in the general population (35.4 per 100,000). Of the 351 patients who underwent alloSCT, 77 who received isoniazid (INH) chemoprophylaxis for 6 months did not develop posttransplantation Tb. However, 5 of the remaining 274 patients who received no chemoprophylaxis developed Tb a median of 12 months (range, 10-47 months) after allografting. Antituberculosis therapy resulted in complete recovery in all cases. In 2 additional patients who were found to have active pulmonary Tb at the time of transplantation, alloSCT was delayed until the infections were treated. Infections of mycobacteria other than Mycobacterium tuberculosis were not observed. The number of patients who received and tolerated INH may not be sufficient for firm conclusions, but the data suggest that, in countries where Tb is prevalent, pre- and posttransplantation follow-up for Tb and the use of INH prophylaxis should be considered.

25 February 2009 in APMIS
Verified
Journal Article
Closed access
PDF file
CACafer Adiguzel
Cafer Adiguzel
SBSuheyla Uyar Bozkurt
Suheyla Uyar Bozkurt
IKIsik Kaygusuz
Isik Kaygusuz
AUAnt Uzay
Ant Uzay
TTTulay Tecimer
Tulay Tecimer
MBMahmut Bayik
Mahmut Bayik

4 January 2010 in European Journal of Haematology
Verified
Journal Article
Closed access
PDF file
IAIsik Atagunduz
Isik Atagunduz
HTHakan Tezcan
Hakan Tezcan
MCMustafa Cetiner
Mustafa Cetiner
OKOzan Kocakaya
Ozan Kocakaya
AUAnt Uzay
Ant Uzay
MBMahmut Bayik
Mahmut Bayik

1 August 1997 in International Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
ZDZeynep Demirçay
Zeynep Demirçay
OGOya Gürbüz
Oya Gürbüz
ALAlpdoǧan
Alpdoǧan
TBTülin Budak
Tülin Budak
DYDeniz Yücelten
Deniz Yücelten
MBMahmut Bayik
Mahmut Bayik

1 December 1998 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
ÖAÖnder Alpdogan
Önder Alpdogan
TBTülin Budak‐Alpdogan
Tülin Budak‐Alpdogan
SRSiret Ratip
Siret Ratip
TFTülin Firatli‐Tuglular
Tülin Firatli‐Tuglular
STSerpil Tanriverdi
Serpil Tanriverdi
TATevfik Akoglu
Tevfik Akoglu